Katarzyna Bednarczuk

Ms. Katarzyna Bednarczuk

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Maciej JóźwikMaciej Jóźwik
Maciej Jóźwik
KBKatarzyna Bednarczuk
Katarzyna Bednarczuk
ZOZofia Osierda
Zofia Osierda
Dermatofibrosarcoma protuberans (DFSP) is a rare proliferative condition representing skin sarcomas which is known to locally recur yet very rarely metastasizes. Its genetic background is a reciprocal translocation t(17;22)(q22;q13) that produces COL1A1-PDGFB gene fusion. Complete resection is the primary treatment. The aim of this review is to outline the pathogenesis, diagnosis, and management of DFSP. A clear-cut distinction between low-to-moderate-grade DFSP with excellent prognosis and high-grade fibrosarcomatous DFSP with a much worse prognosis is underlined. Malignant transformation within DFSP (or high histologic grade), older age, being female, large primary tumor size (≥10 cm), narrow surgical margins of excision (<3 cm), surgical margin positivity for tumor cells, short time to recurrence, numerous recurrences, tumor that was recently rapidly enlarging, and presence of pain in the tumor have all been proposed as clinicopathological risk factors for recurrence and metastasis. A tendency for local growth and local relapses of well- and moderately differentiated DFSPs is an argument for their surgical excision, possibly combined with reconstructive surgery, even in patients of advanced age. Another main point of this review is that cases of DFSP with fibrosarcomatous transformation are a challenge and require careful medical attention. Both anatomopathological evaluation of the presence of lymphovascular space invasion and sentinel lymph node biopsy at DFSP surgery merit further study.

26 January 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Maciej JóźwikMaciej Jóźwik
Maciej Jóźwik
KBKatarzyna Bednarczuk
Katarzyna Bednarczuk
ZOZofia Osierda
Zofia Osierda
JWJoanna Wojtkiewicz
Joanna Wojtkiewicz
JKJanusz Kocik
Janusz Kocik
Maciej JóźwikMaciej Jóźwik
Maciej Jóźwik
Background: Adenomatoid tumor (AT) is a rare benign neoplasm of mesothelial origin, which mainly occurs in the male and female genital tracts. The most common site for AT occurrence in women is the uterus, which makes the presentation in the fallopian tube(s) a rarity with an incidence of approximately 0.5%. The reported extragenital sites include serosal surfaces, adrenal glands, and visceral organs, are even less common. Macroscopically, ATs present as white-grayish or yellowish irregular yet circumscribed firm nodules, often containing cystic components. Owing to a vast array of histomorphological growth patterns, ATs tend to mimic malignancy and trigger overresection. Such clinical situations have been described by several studies for the ovaries, uterus, and fallopian tubes, underlining the importance of differential diagnosis in order to avoid superfluous treatment. Methods: Herein, we report a presentation of an AT at the oviductal lumen, detected incidentally during prophylactic bilateral salpingo-oophorectomy in a 67-year-old patient with a BRCA1 mutation. Results: Immunohistochemical staining revealed a positive expression for calretinin, WT1, and cytokeratin 7, and negative expression for both PAX8 and CD34, thus confirming the diagnosis of AT and excluding tubal malignancy. Conclusions: This report, with a concise review of the global literature on tubal AT, brings attention to the solitary and asymptomatic nature of the tumor. With a clear diagnosis, no surgical radicality is necessary.

27 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
AMAgnieszka Mikłaszewicz
Agnieszka Mikłaszewicz
RSRafał Siedlecki
Rafał Siedlecki
MGMarta Góral
Marta Góral
DFDominik Fidorowicz
Dominik Fidorowicz
DSDaniel Sagan
Daniel Sagan
KBKatarzyna Bednarczuk
Katarzyna Bednarczuk
Introduction and objective: The prostate is a single glandular organ found only in men. Anatomically it is located below the urinary bladder, with the prostatic urethra passing through it. The function of the gland is to secrete fluid, which forms up to 30% of the semen. Physiologically, the dimensions of the organ are approximately 3 cm x 4 cm x 2.5 cm and the weight is 20-25 g. Due to its location, prostate enlargement can lead to constriction of the urethra, which in turn can lead to disturbances in micturition and sexual function. Benign prostatic hyperplasia (BPH) is a common condition affecting men, whose prevalence increases with age. It often leads to lower urinary tract symptoms (LUST) - a group of urinary issues affecting storage (frequency, urgency, incontinence) and voiding (weak stream, hesitancy, straining). For many years, transurethral resection of the prostate (TURP) has remained the gold standard for BPH treatment. However, it is not the only available treatment method. Transurethral incision of the prostate gland (TUIP) is a less invasive method dedicated for less advanced prostatic hyperplasia. This study aims to compare the efficacy and safety of TURP and TUIP based on literature review and comparison of scientific research. Materials and methodology: The article was written based on a thorough analysis of scientific papers available on PubMed and Google Scholar, which serve as verified sources of information.

24 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
MDMagda Downar-Zapolska
Magda Downar-Zapolska
AMAgnieszka Mikłaszewicz
Agnieszka Mikłaszewicz
ASAleksandra Irena Skuza
Aleksandra Irena Skuza
ETEmilia Torbacka
Emilia Torbacka
KSKatarzyna Helena Sergiel
Katarzyna Helena Sergiel
KBKatarzyna Bednarczuk
Katarzyna Bednarczuk
Type 1 diabetes is a chronic autoimmune disorder that could be defined as the immune-mediated destruction of insulin-producing pancreatic β-cells. The outcome of this process is complete insulin deficiency and permanent dependence on exogenous insulin therapy. Despite the innovative methods of insulin delivery systems, constant improvements in insulin formulations, and the introduction of continuous glucose monitors (CGMs), the management of blood glucose levels and keeping them within the recommended range prove to be difficult for patients, who additionally face the risk of hypoglycemic episodes and long-term complications associated with type 1 diabetes. The purpose of this review is to examine current and new emerging additional therapies used in the management of type 1 diabetes, with particular focus on adjunct non-insulin treatments, their mechanisms, effectiveness and safety profiles. This review was written using databases such as PubMed with direct attention to new forms of treatment in type 1 diabetes: pharmacological and immune-focused. The adjunct pharmacological therapies which include amylin analogue, GLP-1 receptor agonists, SGLT inhibitors and metformin have shown to be potentially beneficial for patients with type 1 diabetes, improving glycemic control, reducing insulin dose needs while facilitating weight loss. On the other hand, the immune-based therapies and therapies utilizing stem cells aim to restore the function of insulin-producing pancreatic β-cells or preserve it for as long as possible, slowing down the progression of the disease. However, the introduction of new therapies remains a concern, especially the risk of hypoglycemia or diabetic ketoacidosis (DKA). Ultimately, the new emerging therapies used in addition to insulin therapy have proven to be beneficial for the patients, but further research is needed in order to evaluate their effectiveness and ensure safety. Methodology: The review was written based on scientific papers and articles available on PubMed and Google Scholar.

24 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
DSDaniel Sagan
Daniel Sagan
MGMarta Góral
Marta Góral
RSRafał Siedlecki
Rafał Siedlecki
DFDominik Fidorowicz
Dominik Fidorowicz
KSKatarzyna Helena Sergiel
Katarzyna Helena Sergiel
KBKatarzyna Bednarczuk
Katarzyna Bednarczuk
Sodium-glucose cotransporter 2 (SGLT2) inhibitors, or gliflozins, represent one of the most significant pharmacological breakthroughs in modern cardiovascular and renal medicine. Originally developed as glucose-lowering agents for type 2 diabetes, these medications have demonstrated profound, life-saving cardiovascular benefits in patients, regardless of their glycemic status. This shift from a "glucocentric" to an "organoprotective" paradigm is driven by a complex array of pleiotropic mechanisms that transcend simple osmotic diuresis. This work provides a comprehensive analysis of the multifaceted physiological pathways through which SGLT2 inhibitors exert their effects. Key mechanisms explored include the optimization of myocardial bioenergetics through ketone body utilization, the stabilization of ion exchange, the restoration of tubuloglomerular feedback, reduction of epicardial adipose tissue, microbiome management and improvement in cardiac muscle remodelling. This review evaluates the landmark clinical evidence from pivotal trials such as EMPA-REG, DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, DELIVER, DAPA-MODA, DAPA-CKD, CREDENCE, EMPA-KIDNEY, DAPA-MI and EMPACT-MI; exploring the SGLT2i role in patients with heart failure and chronic kidney disease. These studies have established SGLT2 inhibitors as the first class of therapy to show consistent mortality and morbidity benefits across the entire spectrum of left ventricular ejection fraction. The work also addresses recent 2024 to 2025 data regarding early implementation in the post-myocardial infarction setting and the emerging role of the gut-kidney-heart axis in modulating systemic inflammation. Materials and Methods: The article was written based on scientific papers available on PubMed and Google Scholar.

18 June 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KSKatarzyna Helena Sergiel
Katarzyna Helena Sergiel
KBKatarzyna Bednarczuk
Katarzyna Bednarczuk
MDMagda Downar-Zapolska
Magda Downar-Zapolska
DFDominik Fidorowicz
Dominik Fidorowicz
MGMarta Góral
Marta Góral
ETEmilia Torbacka
Emilia Torbacka
Dementia is a significant public health concern that is expected to worsen in the future due to the growing proportion of elderly people in the population. One of the important and modifiable risk factors for this condition is alcohol consumption. The effect of alcohol on the development of dementia is dose-dependent; excessive intake increases the overall risk of developing dementia and also leads to a characteristic alcohol-induced neurocognitive disorder, sometimes referred to as alcohol-related dementia. Even moderate alcohol intake results in detectable changes in the brain, observable from a young age. These effects are caused by alcohol-induced neurotoxicity, including mechanisms such as neuroinflammation, the production of reactive oxygen species (ROS), acetaldehyde toxicity, and thiamine deficiency. This review summarizes the impact of alcohol consumption on the development of dementia, as well as the mechanisms of neurotoxicity caused by ethanol and its metabolic products. Methodology: The study was based on scientific articles available in the PubMed and Google Scholar databases.